Shaping the Future of Payload Delivery for Cell and Gene Therapies.
With our specialized expertise in viral vector development and optimization to ensure efficient and effective therapeutic delivery and accelerate breakthroughs in disease treatment.
We specialize in providing tailored viral vector solutions to empower your research and development initiatives for advanced therapies. With our cutting-edge technologies and extensive expertise, we deliver high-quality viral vectors designed to meet the specific needs of your therapeutic and target tissue, facilitating advancements in targeted delivery.
Through innovative custom cell line development solutions.
Carrigent is dedicated to advancing research through innovative custom cell line development solutions that result in higher titers and larger packaging inserts. Our expertise in viral vector and gene-editing technologies enables us to create tailored cell lines that meet the unique demands of your vector.
By integrating advanced methodologies with our state-of-the-art technologies, we empower researchers to explore new frontiers in protein function, drug discovery, and cellular behavior analysis.
We offer custom process development services and preclinical viral vector production for researchers in need of knowledgeable yet flexible partners.
Preclinical Viral Vector Process Development and Production
Carrigent offers custom process development services as well as preclinical production of virus at a range of scales. We currently can produce virus at up to a 200L scale.
Rather than fitting your process to a fixed, inefficient production platform, Carrigent maintains a diversity of production technologies to identify the process that is most effective for your application.
We offer a unique technology licensing approach.
Carrigent offers both exclusive and non-exclusive licensing of our technologies with an approach that de-risks your investment at early stages of development. Custom-designed vector and cell line technologies are provided royalty-free for the entirety of your product's lifecycle.
Our internally-developed technologies are free to access through early-stage clinical development to maximize your ability to complete your development objectives, with milestone-based payments and royalties not applied until late clinical and commercial stages of your therapeutic.